Results 141 to 150 of about 2,401,098 (314)
Alternative Workflows for Transnational Missing Persons Identifications
Forensic Science International: Synergy, 2023 Sara Katsanis
doaj +1 more source
The Missing Persons in the Republic of Croatia [PDF]
, 2013 Ksenija Butorac +2 more
openalex +1 more source
FEBS Letters, EarlyView.The Ile181Asn variant of human UDP‐xylose synthase (hUXS1), associated with a short‐stature genetic syndrome, has previously been reported as inactive. Our findings demonstrate that Ile181Asn‐hUXS1 retains catalytic activity similar to the wild‐type but exhibits reduced stability, a looser oligomeric state, and an increased tendency to precipitate ...
Tuo Li +2 more
wiley +1 more source
, 2015 Abstract This chapter discusses the core articles of the Geneva Conventions (GCs) and First Additional Protocol to the Geneva Conventions (AP I) dealing with the issue of missing persons. These are Article 16 GC I, Article 19 GC II, Articles 17, 119, 122, and 123 GC III, Articles 133 and 136–140 GC IV, and Articles 32 and 33 AP I.
openaire +1 more source
PICALM::MLLT10 translocated leukemia
FEBS Letters, EarlyView.This comprehensive review of PICALM::MLLT10 translocated acute leukemia provides an in‐depth review of the structure and function of CALM, AF10, and the fusion oncoprotein (1). The multifaceted molecular mechanisms of oncogenesis, including nucleocytoplasmic shuttling (2), epigenetic modifications (3), and disruption of endocytosis (4), are then ...
John M. Cullen +7 more
wiley +1 more source
β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1
Molecular Oncology, EarlyView.Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero +8 more
wiley +1 more source
Molecular Oncology, EarlyView.PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham +21 more
wiley +1 more source
A Qualitative Study of Grief among Family Members of Missing Persons in Southern Sri Lanka [PDF]
, 2021 Amila Isuru +2 more
openalex +1 more source